医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Reverse Medical Corporation Announces Strategic Alliance in Japan

2013年06月11日 PM07:40
このエントリーをはてなブックマークに追加


 

IRVINE, Calif.

Reverse Medical Corporation today announced entering into a strategic partnership agreement with Century Medical, Inc. (CMI), for distribution of the Reverse Medical products in Japan. CMI (a subsidiary of ITOCHU Corporation) is the premiere medical device product distributor in Japan. Commenting on the Agreement, Reverse Medical President & CEO Mr. Jeffrey Valko stated, “We are extremely pleased to have CMI as our strategic partner. The depth and strength of CMI’s network throughout Japan will greatly assist Reverse Medical in developing a leadership role in treating patients with complex Neurovascular disorders. CMI has made a significant financial commitment to both Reverse, and to funding the regulatory approval process for the Reverse products in Japan, and will concentrate on moving Reverse’s Barrel™ Vascular Reconstruction Device (VRD), Micro Vascular Plug (MVP™) embolization device, and Reverse’s other products through the Japanese regulatory approval process. We continue to actively develop similar partnerships for European distribution of our products.”

Nobuyuki Sakai, MD (Kobe, Japan) stated, “Reverse Medical has developed several unique and useful technologies for Neuro interventional procedures. I am pleased by CMI’s recognition of the innovative and unique differentiating value of the Reverse technologies, and the promise for significant market adoption in Japan.”

CMI President & CEO Mr. Akira Hoshino added, “We are truly impressed by the ongoing innovation from Reverse Medical and the speed with which they’ve achieved product development, regulatory approvals and successful human clinical experience. CMI believes the Japanese market for unique products to treat patients with complex neurovascular conditions remains vastly under-penetrated, with significant opportunity for advanced technology adoption and growth.” CMI and Reverse Medical are progressing through various milestones toward regulatory approvals from the Japanese Ministry of Health, Labor and Welfare approvals.

Reverse Medical Corporation, based in Irvine, California, is a privately held medical device company focused on expanding the endovascular management of peripheral and neurovascular disease. The technology pipeline includes innovative, state-of-the-art treatments for a broad spectrum of peripheral and neurovascular disorders and disease.

CONTACT

Reverse Medical Corporation
Jeffrey Valko, President & CEO
949-215-0660,
ext. 200

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表